A panelist discusses how chronic graft-versus-host disease affects 30-70% of allogeneic transplant patients across eight ...

Justiz Vaillant AA, Modi P, Mohammadi O. Graft-versus-host disease. In: StatPearls. StatPearls Publishing; 2024. The Leukemia and Lymphoma Society. Graft-versus-host disease. Matsukuma KE ...

Texas A&M’s Simrit Parmar partners with Saudi hospital for groundbreaking cell therapy trials targeting ALS and aplastic ...

The "Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis of the GVHD clinical trial ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

GvHD Treatment Market set for robust expansion from 2025 to 2035, driven by novel therapies, R&D investments, and rising transplant procedures.